arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

KYNTRA BIO, INC.

KYNB
$7.24 ▲ +0.24 (+3.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bullish
auto_awesome

Analytical Summary

KYNTRA BIO, INC. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $29.3M
Dividend Yield
Revenue Growth 36.5%
Op. Margin -369.7%
ROIC 24.9%
FCF / Share $-3.43
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.74M
↑ +36.5%
Net Income Profit after all expenses
$-15.20M
↓ -6.9%
Operating Margin Operating profit as % of sales
-369.7%
↓ -62.5%
FCF / Share Free cash flow per share
$-3.43
↓ -647.7%
Long-Term Debt Long-term obligations
$75.00M
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
3
Financial Health
68
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters